Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs
Open Access
- 4 June 2021
- journal article
- research article
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 6, 140
Abstract
Introduction: Access to and the cost of induction treatment for cryptococcal meningitis (CM) is rapidly changing. The newly-announced price for flucytosine ($0.75 per 500 mg pill) and possibly lower prices for liposomal amphotericin B (AmB-L) create opportunities to reduce CM treatment costs compared to the current standard treatment in low- and middle-income countries. Methods: We developed an Excel-based cost model to estimate health system treatment costs for CM over a two-week induction phase for multiple treatment combinations, newly feasible with improved access to flucytosine and AmB-L. CM treatment costs include medications, laboratory tests and other hospital-based costs (bed-day costs and healthcare worker time). We report results from applying the model using country-specific information for South Africa, Uganda, Nigeria, and Botswana. Results: A 14-day induction-phase of seven days of inpatient AmB-D with flucytosine, followed by seven days of high-dose fluconazole as an outpatient, will cost health systems less than a 14-day hospital stay with AmB-D and fluconazole. If daily AmB-L replaces AmB-D for those with baseline renal dysfunction, with a cost of $50 or less per 50 mg vial, incremental costs would still be less than the AmB-D with fluconazole regimen. Simple oral combinations (e.g., seven days of flucytosine with fluconazole as an inpatient) are practical when AmB-D is not available, and treatment costs would remain less than the current standard treatment. Conclusions: Improved access to, and lower prices for flucytosine and AmB-L create opportunities for improving CM treatment regimens. An induction regimen of flucytosine and AmB-D for seven days is less costly than standard care in the settings studied here. As this regimen has also been shown to be more effective than current standard care, countries should prioritize scaling up flucytosine access. The cost of AmB-L based regimens is highly dependent on the price of AmB-L, which currently remains unclear.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (RO1AI118511, K23AI38851)
- CDC Foundation (Project950)
- National Institute for Health Research (RP-2017-08-ST2-012)
- Wellcome Trust (212638)
This publication has 15 references indexed in Scilit:
- Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countriesThe Lancet Infectious Diseases, 2019
- AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority TrialTrials, 2018
- Antifungal Combinations for Treatment of Cryptococcal Meningitis in AfricaNew England Journal of Medicine, 2018
- Treatment eligibility and retention in clinical HIV care: A regression discontinuity study in South AfricaPLOS Medicine, 2017
- Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysisThe Lancet Infectious Diseases, 2017
- High rates of viral suppression in adults and children with high CD4+ counts using a streamlined ART delivery model in the SEARCH trial in rural Uganda and KenyaJournal of the International AIDS Society, 2017
- Effects of high CD4 cell counts on death and attrition among HIV patients receiving antiretroviral treatment: an observational cohort studyScientific Reports, 2017
- Global access to antifungal therapy and its variable costJournal of Antimicrobial Chemotherapy, 2016
- Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countriesThe Lancet Infectious Diseases, 2013
- Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungalJournal of Antimicrobial Chemotherapy, 2013